See more : CSMall Group Limited (1815.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Pyxis Oncology, Inc. (PYXS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pyxis Oncology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Nutranomics, Inc. (NNRX) Income Statement Analysis – Financial Results
- Looks Health Services Limited (LOOKS.BO) Income Statement Analysis – Financial Results
- Mapfre, S.A. (MAP.MC) Income Statement Analysis – Financial Results
- Gravitas Education Holdings, Inc. (GEHI) Income Statement Analysis – Financial Results
- Pure Transit Technologies, Inc. (PTTL) Income Statement Analysis – Financial Results
Pyxis Oncology, Inc. (PYXS)
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.00M | 1.84M | 1.25M | 444.00K | 0.00 |
| Gross Profit | -2.00M | -1.84M | -1.25M | -444.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 49.59M | 86.13M | 51.05M | 9.05M | 1.22M |
| General & Administrative | 32.61M | 37.35M | 18.66M | 3.85M | 1.66M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 32.61M | 37.35M | 18.66M | 3.85M | 1.66M |
| Other Expenses | 0.00 | 0.00 | 181.00K | 0.00 | 0.00 |
| Operating Expenses | 82.20M | 123.48M | 69.72M | 12.89M | 2.88M |
| Cost & Expenses | 82.20M | 123.48M | 69.72M | 12.89M | 2.88M |
| Interest Income | 6.63M | 2.76M | 23.00K | 66.00K | 107.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.00M | 1.84M | 1.25M | 444.00K | 2.88M |
| EBITDA | -78.49M | -122.77M | -69.07M | -12.43M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -82.20M | -123.48M | -69.72M | -12.89M | -2.88M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 8.41M | 2.76M | -6.26M | 66.00K | 107.00K |
| Income Before Tax | -73.79M | -120.72M | -75.98M | -12.83M | -2.77M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -2.76M | 5.56M | -66.00K | -107.00K |
| Net Income | -73.79M | -117.95M | -81.54M | -12.76M | -2.67M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.85 | -3.57 | -2.53 | -0.37 | -0.08 |
| EPS Diluted | -1.85 | -3.57 | -2.53 | -0.37 | -0.08 |
| Weighted Avg Shares Out | 39.90M | 33.03M | 32.22M | 34.31M | 34.31M |
| Weighted Avg Shares Out (Dil) | 39.90M | 33.03M | 32.22M | 34.31M | 34.31M |
Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
Q2 2024 EPS Estimates for Pyxis Oncology, Inc. (NASDAQ:PYXS) Decreased by Analyst
Pyxis Oncology, Inc. (PYXS) Reports Q1 Loss, Tops Revenue Estimates
Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference
Does Pyxis Oncology (PYXS) Have the Potential to Rally 61.29% as Wall Street Analysts Expect?
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3 Biotech Stocks to Buy on the Dip: March 2024
Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights
All You Need to Know About Pyxis Oncology (PYXS) Rating Upgrade to Buy
Source: https://incomestatements.info
Category: Stock Reports